Cancer compound is scheduled to enter Phase I studies later this year.
SynCo Bio Partners will fill and finish batches of OncoMed Pharmaceuticals’ anticancer mAb OMP-21M18. This is OncoMed’s lead compound and is expected to enter Phase I trials this year.
OncoMed recently inked a deal with GlaxoSmithKline valued at $1.4 billion to advance its cancer stem-cell antibody therapeutics. OMP-21M18, represent a key project in this alliance.
